Hypercalcemia and cancer: Differential diagnosis and treatment.
TLDR
The initial workup, differential diagnoses, confirmatory laboratory testing, imaging, and medical and surgical management of hypercalcemia are described in the patient with cancer.Abstract:
Incidentally detected hypercalcemia usually presents in an indolent manner and is most likely caused by primary hyperparathyroidism. In contrast, hypercalcemia in the patient with a history of cancer presents in a wide range of clinical settings and may be severe enough to warrant hospitalization. This form of hypercalcemia is usually secondary to hypercalcemia of malignancy and can be fatal. Hypercalcemia of malignancy is most commonly mediated by tumoral production of parathyroid hormone-related protein or by cytokines activating osteoclast degradation of bone. The initial workup, differential diagnoses, confirmatory laboratory testing, imaging, and medical and surgical management of hypercalcemia are described in the patient with cancer.read more
Citations
More filters
Hipercalcemia maligna: características clínicas y factores asociados a su presentación en un centro oncológico de referencia nacional análisis de casos y controles fase I
TL;DR: El sexo femenino, los valores de albumina normales y el indice ofsky de 70 o mas se comportaron como factores protectores asociados a la presentacion de hipercalcemia maligna mientras que the presencia of metastasis es un factor de riesgo.
Journal ArticleDOI
Title Changes in the Mineral Composition of Rat Femoral Bones Induced by Implantation of LNCaP Prostate Cancer Cells and Dietary Supplementation.
Dorota Skrajnowska,Agata Jagielska,Anna Ruszczyńska,Barbara Wagner,Wojciech Bielecki,Barbara Bobrowska-Korczak +5 more
TL;DR: In this paper, the effect of chronic dietary intake of calcium, iron and zinc, administered in doses corresponding maximally to twice their level in a standard diet, on homeostasis of selected elements (Ca, K, Zn, Fe, Cu, Sr, Ni, Co, Mn and Mo) in the femoral bones of healthy rats and rats with implanted cancer cells of the LNCaP line.
Journal ArticleDOI
Calcium selective optical sensor based on calmodulin functionalized porous silicon
TL;DR: In this paper, an optical calcium sensor is fabricated using calmodulin surface functionalized macro-porous silicon, which shows effective selectivity and multi-parametric optical response for calcium ions.
Journal ArticleDOI
Imaging features of hypercalcemia: A primer for emergency radiologists.
Angela Spierling,Elias Kikano,Kaushik Chagarlamudi,Derek Vos,Sanjay Rao,Daniel A. Smith,Nikhil H. Ramaiya +6 more
TL;DR: A review of common and uncommon etiologies of hypercalcemia, details their underlying mechanisms, and identifies the most important associated imaging findings can be found in this paper, where the authors suggest that it is important for radiologists to be familiar with these etiology and imaging findings, particularly in the emergency setting since hypercalcmia may represent the only significant laboratory abnormality associated with the presenting condition.
Journal ArticleDOI
Cancer Cachexia: Its Mechanism and Clinical Significance.
Hiroki Nishikawa,Masahiro Goto,Shinya Fukunishi,Akira Asai,Shuhei Nishiguchi,Kazuhide Higuchi +5 more
TL;DR: A review of the current status of cachexia, the mechanisms of which have been elucidated in recent years, especially from the perspective of advanced cancer, can be found in this paper.
References
More filters
Journal ArticleDOI
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
David E. Hughes,Kenneth R. Wright,Harry L. Uy,Harry L. Uy,Akira Sasaki,Toshiyuki Yoneda,David G. Roodman,David G. Roodman,Gregory R. Mundy,Brendan F. Boyce +9 more
TL;DR: Osteoclast apoptosis may be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.
Journal ArticleDOI
Clinical practice. Hypercalcemia associated with cancer.
TL;DR: A 47-year-old woman with a history of breast cancer presents with confusion and dehydration and bone scintigraphy reveals no evidence of skeletal involvement by the tumor.
Journal ArticleDOI
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Pierre Major,Alain Lortholary,J. Hon,E Abdi,Gordon B. Mills,H D Menssen,F Yunus,Richard Bell,Jean-Jacques Body,E Quebe-Fehling,John W. Seaman +10 more
TL;DR: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
Journal ArticleDOI
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Fred Saad,Janet E. Brown,C. Van Poznak,Toni Ibrahim,Salomon M. Stemmer,Alison Stopeck,Ingo Diel,Shunji Takahashi,Neal D. Shore,David H. Henry,Carlos H. Barrios,T. Facon,Francis M. Senecal,Karim Fizazi,Lei Zhou,Alan H. Daniels,P. Carriere,Roger Dansey +17 more
TL;DR: In this combined analysis of three prospective trials, Osteonecrosis of the jaw was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients.
Journal ArticleDOI
Denosumab and bisphosphonates: different mechanisms of action and effects.
TL;DR: It is suggested that the key pharmacological differences between denosumab and the bisphosphonates reside in the distribution of the drugs within bone and their effects on precursors and mature osteoclasts, which may explain differences in the degree and rapidity of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions.